Lam Research Corporation Reports Financial Results for the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Lam Research Corporation Reports Financial Results for the Quarter Ended June 29, 2014

FREMONT, CA --(Marketwired - July 30, 2014) - Lam Research Corp. ( NASDAQ : LRCX ) today announced financial results for the quarter ended June 29, 2014.

Highlights for the June 2014 quarter were as follows:

  • Revenue of $1,249 million, up 2% from the prior quarter 
  • GAAP gross margin of 44.6%, GAAP operating margin of 17.3% and GAAP diluted EPS of $1.35 
  • Non-GAAP gross margin of 46.4%, non-GAAP operating margin of 20.6%, and non-GAAP diluted EPS of $1.25  
   
Financial Highlights for the Quarters Ended June 29, 2014 and March 30, 2014  
(in thousands, except per-share data and percentages)  
                   
U.S. GAAP  
    June 2014     March 2014     Change Q/Q  
                       
Revenue   $ 1,248,797     $ 1,227,392     +2 %
Gross margin as percentage of revenue     44.6 %     43.2 %   +140bps  
Operating margin as percentage of revenue     17.3 %     15.6 %   +170 bps  
Diluted EPS   $ 1.35     $ 0.96     +41 %
                       
Non-GAAP  
      June 2014       March 2014     Change Q/Q  
                       
Revenue   $ 1,248,797     $ 1,227,392     +2 %
Gross margin as percentage of revenue     46.4 %     45.5 %   +90 bps  
Operating margin as percentage of revenue     20.6 %     20.2 %   +40 bps  
Diluted EPS   $ 1.25     $ 1.26     -1 %
                       

GAAP Financial Results Revenue for the period was $1,249 million, gross margin was $557.0 million, or 44.6% of revenue, operating expenses were $341.2 million, operating margin was 17.3% of revenue, and net income was $233.4 million, or $1.35 per diluted share on a GAAP basis. This compares to revenue of $1,227 million, gross margin of $530.8 million, or 43.2% of revenue, operating expenses of $338.9 million, operating margin of 15.6% of revenue, and net income of $164.4 million, or $0.96 per diluted share, for the March 2014 quarter. Our June 2014 results benefited from an $83 million gain on sale of non-essential real estate.

Non-GAAP Financial Results Non-GAAP gross margin was $579.9 million or 46.4% of revenue, non-GAAP operating expenses were $322.2 million, non-GAAP operating margin was 20.6% of revenue, and non-GAAP net income was $217.2 million, or $1.25 per diluted share. This compares to non-GAAP gross margin of $558.9 million or 45.5% of revenue, non-GAAP operating expenses of $311.0 million, non-GAAP operating margin of 20.2% of revenue, and non-GAAP net income of $216.4 million, or $1.26 per diluted share for the March 2014 quarter.

"Lam's June quarter and fiscal year results demonstrate strong execution of our growth strategy during a transformative period for the Company," stated Martin Anstice, Lam Research's president and chief executive officer. "­­­­­­­­­­­­­­­­­­­­­­­­­­­­­Fiscal year results included record revenues in each successive quarter and operating income more than doubled year-over-year. Central to our financial and operational outperformance is our close collaboration with our customers in addressing the technical and economic challenges of scaling. We believe these efforts provide opportunities to build upon this foundation with market growth and share gains at the key inflections that will drive wafer fab equipment investment for the foreseeable future." 

Balance Sheet and Cash Flow Results Cash and cash equivalents, short-term investments, and restricted cash and investment balances increased to $3.2 billion at the end of the June 2014 quarter compared to $2.9 billion at the end of the March 2014 quarter. This increase was primarily the result of approximately $246 million in cash flows from operating activities and approximately $135 million of cash proceeds on sale of assets during the June 2014 quarter and was partially offset by approximately $42 million of capital expenditures and approximately $40 million of stock repurchases.

Deferred revenue and deferred profit balances at the end of the June 2014 quarter decreased to $361.6 million and $235.9 million, respectively, as compared to $431.5 million and $257.3 million, respectively, at the end of the March 2014 quarter. Lam's deferred revenue balance does not include shipments to Japanese customers, to whom title does not transfer until customer acceptance. Shipments to Japanese customers are classified as inventory at cost until the time of acceptance. The anticipated future revenue from shipments to Japanese customers was approximately $34.0 million as of June 29, 2014.

Geographic Distribution The geographic distribution of shipments and revenue during the June 2014 quarter is shown in the following table:

             
Region   Shipments     Revenue  
United States   23 %   18 %
Europe   7 %   6 %
Japan   14 %   14 %
Korea   25 %   28 %
Taiwan   18 %   20 %
Southeast Asia   4 %   3 %
China   9 %   11 %
             

Outlook For the September 2014 quarter, Lam is providing the following guidance: 

                 
    GAAP Reconciling Items Non-GAAP
Shipments   $1.11 Billion +/- $50 Million - $1.11 Billion +/- $50 Million
Revenue   $1.15 Billion +/- $50 Million - $1.15 Billion +/- $50 Million
Gross margin   43.7% +/- 1% $21 Million 45.5% +/- 1%
Operating margin   14.3% +/- 1% $37 Million 17.5% +/- 1%
Earnings per share   $0.71 +/- $0.07 $38 Million $0.92 +/- $0.07
Diluted share count   177 Million   177 Million
         

The information provided above is only an estimate of what the Company believes is realizable as of the date of this release. GAAP to non-GAAP reconciling items provided include only those items that are known and can be estimated as of the date of this release. Actual results will vary from this model and the variations may be material. Reconciling items included above are as follows:

  • Gross margin - amortization related to intangible assets acquired in the Novellus transaction, $21 million.
  • Operating margin - amortization related to intangible assets acquired in the Novellus transaction, $37 million.
  • Earnings per share - amortization related to intangible assets acquired in the Novellus transaction, $37 million; the amortization of convertible note discounts, $8 million; and the associated tax benefit for non-GAAP items ($7) million, totaling $38 million.

Use of Non-GAAP Financial Results In addition to U.S. GAAP results, this press release also contains non-GAAP financial results. The Company's non-GAAP results for both the June 2014 and March 2014 quarters exclude rationalization of certain product configurations, amortization related to intangible assets acquired in the Novellus transaction, the amortization of convertible note discounts, and tax expense (benefit) of non-GAAP items. Additionally, the June 2014 quarter non-GAAP results exclude the release of acquisition-related inventory fair value impacts, restructuring charges, cost associated with the disposition of business, gain on sale of real estate, and tax benefit on successful resolution of certain tax matters. The March 2014 quarter non-GAAP results also exclude the impairment of a long-lived asset and expenses associated with the synthetic lease impairment.

Management uses non-GAAP gross margin, operating income, operating expenses, operating margin, net income, and net income per diluted share to evaluate the Company's operating and financial results. The Company believes the presentation of non-GAAP results is useful to investors for analyzing business trends and comparing performance to prior periods, along with enhancing investors' ability to view the Company's results from management's perspective. Tables presenting reconciliations of non-GAAP results to U.S. GAAP results are included at the end of this press release and on the Company's web site at http://investor.lamresearch.com .

Caution Regarding Forward-Looking Statements Statements made in this press release that are not of historical fact are forward-looking statements and are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to, but are not limited to, the anticipated revenue from shipments to Japanese customers, our ability to continue to successfully execute our growth strategy during transformative periods, our ability to continue to successfully collaborate closely with customers, our ability to address the technical and economic challenges of scaling, our ability to achieve market growth and share gains at key inflections, our ability to obtain and maintain market share in wafer fab equipment investment, our ability to deliver growth and value for our customers and our shareholders, and our guidance for shipments, revenue, gross margin, operating margin, and earnings per share. Some factors that may affect these forward-looking statements include: business conditions in the consumer electronics industry, the semiconductor industry and the overall economy; the strength of the financial performance of our existing and prospective customers; the introduction of new and innovative technologies; the occurrence and pace of technology transitions and conversions; the actions of our competitors, consumers, semiconductor companies and key suppliers and subcontractors; and the success of research and development and sales and marketing programs. These forward-looking statements are based on current expectations and are subject to uncertainties and changes in condition, significance, value and effect as well as other risks detailed in documents filed by us with the Securities and Exchange Commission, including specifically our report on Form 10-K for the year ended June 30, 2013 and Forms 10-Q for the three months ended September 29, 2013, December 29, 2013 and March 30, 2014. These uncertainties and changes could cause actual results to vary from expectations. The Company undertakes no obligation to update the information or statements made in this press release.

About Lam Research Lam Research Corp. ( NASDAQ : LRCX ) is a trusted global supplier of innovative wafer fabrication equipment and services to the semiconductor industry. Lam's broad portfolio of market-leading etch, deposition, strip, and wafer cleaning solutions help customers achieve success on the wafer by enabling device features that are 1,000 times smaller than a grain of sand, resulting in smaller, faster, and more power-efficient chips. Through collaboration, continuous innovation and delivering on commitments, Lam is transforming atomic-scale engineering and enabling our customers to shape the future of technology. Based in Fremont, Calif., Lam Research is an S&P 500 ® company whose common stock trades on the NASDAQ Global Select Market under the symbol LRCX. For more information, please visit http://www.lamresearch.com .

   
LAM RESEARCH CORPORATION  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
(in thousands, except per share data and percentages)  
                               
    Three Months Ended     Twelve Months Ended  
    June 29,     March 30,     June 30,     June 29,     June 30,  
    2014     2014     2013     2014     2013  
    (unaudited)     (unaudited)     (unaudited)     (unaudited)     (1)  
Revenue   $ 1,248,797     $ 1,227,392     $ 986,214     $ 4,607,309     $ 3,598,916  
                                         
  Cost of goods sold     691,761       696,594       572,287       2,599,828       2,195,857  
    Gross margin     557,036       530,798       413,927       2,007,481       1,403,059  
    Gross margin as a percent of revenue     44.6 %     43.2 %     42.0 %     43.6 %     39.0 %
Research and development     185,449       185,978       180,220       716,471       683,688  
Selling, general and administrative     155,737       152,883       147,209       613,341       601,300  
    Total operating expenses     341,186       338,861       327,429       1,329,812       1,284,988  
    Operating income     215,850       191,937       86,498       677,669       118,071  
    Operating margin as a percent of revenue     17.3 %     15.6 %     8.8 %     14.7 %     3.3 %
Gain on sale of real estate     83,090       -       -       83,090       -  
Other expense, net     (9,442 )     (9,855 )     (12,251 )     (37,396 )     (51,413 )
    Income (loss) before income taxes     289,498       182,082       74,247       723,363       66,658  
Income tax expense (benefit)     56,103       17,686       (11,460 )     91,074       (47,221 )
    Net income   $ 233,395     $ 164,396     $ 85,707     $ 632,289     $ 113,879  
Net income per share:                                        
  Basic net income per share   $ 1.44     $ 1.01     $ 0.53     $ 3.84     $ 0.67  
  Diluted net income per share   $ 1.35     $ 0.96     $ 0.50     $ 3.62     $ 0.66  
Number of shares used in per share calculations:                                        
  Basic     162,215       162,238       162,520       164,741       168,932  
  Diluted     173,345       171,636       169,722       174,503       173,430  
Cash dividend declared per share   $ 0.18     $ -     $ -     $ 0.18     $ -  
                                         
(1) Derived from audited financial statements  
                                         
 
LAM RESEARCH CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
             
    June 29,   March 30,   June 30,
    2014   2014   2013
    (unaudited)   (unaudited)   (1)
ASSETS                  
Cash and cash equivalents   $ 1,452,677   $ 1,292,301   $ 1,162,473
Short-term investments     1,612,967     1,462,171     1,334,745
Accounts receivable, net     800,616     818,390     602,624
Inventories     740,503     717,356     559,317
Other current assets     176,899     157,131     134,670
  Total current assets     4,783,662     4,447,349     3,793,829
Property and equipment, net     543,496     552,591     603,910
Restricted cash and investments     146,492     143,914     166,536
Goodwill and intangible assets     2,360,303     2,408,913     2,526,541
Other assets     159,353     154,600     159,499
  Total assets   $ 7,993,306   $ 7,707,367   $ 7,250,315
                   
LIABILITIES AND STOCKHOLDERS' EQUITY                  
Current liabilities   $ 1,582,001   $ 1,542,705   $ 1,404,475
                   
Long-term debt and capital leases   $ 817,202   $ 810,688   $ 789,256
Income taxes payable     258,357     251,080     246,479
Other long-term liabilities     122,662     111,346     134,313
  Total liabilities   $ 2,780,222   $ 2,715,819   $ 2,574,523
                   
Senior convertible notes     183,349     184,256     186,920
                   
Stockholders' equity (2)     5,029,735     4,807,292     4,488,872
  Total liabilities and stockholders' equity   $ 7,993,306   $ 7,707,367   $ 7,250,315
                   
(1) Derived from audited financial statements
 
(2) Common shares issued and outstanding were 162,350 as of June 29, 2014, 161,988 shares as of March 30, 2014, and 162,873 shares as of June 30, 2013.
   
LAM RESEARCH CORPORATION  
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS  
(in thousands)  
                               
    Three Months Ended     Twelve Months Ended  
    June 29,     March 30,     June 30,     June 29,     June 30,  
    2014     2014     2013     2014     2013  
    (unaudited)     (unaudited)     (unaudited)     (unaudited)     (1)  
CASH FLOWS FROM OPERATING ACTIVITIES:                                        
Net income   $ 233,395     $ 164,396     $ 85,707     $ 632,289     $ 113,879  
Adjustments to reconcile net income to net cash providedby operating activities:                                        
  Depreciation and amortization     71,115       73,256       76,051       292,254       304,116  
  Deferred income taxes     (4,104 )     (816 )     (22,884 )     7,537       (70,155 )
  Impairment of long-lived assets     -       4,000       -       11,632       -  
  Equity-based compensation expense     33,085       24,334       25,241       103,700       99,330  
  Impairment of investment     -       -       -       -       3,711  
  Income tax benefit on equity-based compensation plans     6,269       (296 )     364       5,973       (483 )
  Excess tax benefit on equity-based compensation plans     (6,361 )     296       (364 )     (6,065 )     539  
  Amortization of convertible note discount     8,411       8,313       8,028       33,063       31,558  
  Gain on sale of real estate     (83,090 )     -       -       (83,090 )     -  
  Other, net     8,241       2,741       5,342       12,669       37,201  
  Changes in operating asset and liabilities:     (21,070 )     13,986       (2,497 )     (292,913 )     200,237  
    Net cash provided by operating activities     245,891       290,210       174,988       717,049       719,933  
                                         
CASH FLOWS FROM INVESTING ACTIVITIES:                                        
Capital expenditures and intangible assets     (41,764 )     (41,638 )     (43,140 )     (145,503 )     (160,795 )
Cash paid for business acquisition     (11,839 )     -       (800 )     (30,227 )     (9,916 )
Net purchases of available-for-sale securities     (155,035 )     (82,744 )     (6,442 )     (283,966 )     (58,405 )
(Issuance) repayments of notes receivable     -       -       (10,000 )     10,000       (10,000 )
Proceeds from sale of assets     134,762       -       -       156,397       660  
Transfer of restricted cash and investments     (637 )     28,572       (328 )     28,085       (181 )
    Net cash used for investing activities     (74,513 )     (95,810 )     (60,710 )     (265,214 )     (238,637 )
                                         
CASH FLOWS FROM FINANCING ACTIVITIES:                                        
Principal payments on long-term debt and capital lease obligations     (739 )     (112 )     (698 )     (1,658 )     (2,234 )
Excess tax benefit on equity-based compensation plans     6,361       (296 )     364       6,065       (539 )
Treasury stock purchases     (40,249 )     (52,415 )     (2,275 )     (244,859 )     (955,661 )
Reissuances of treasury stock related to employee stock purchase plan     14,597       13,210       12,846       42,926       31,265  
Proceeds from issuance of common stock     8,657       5,111       16,713       34,791       39,379  
    Net cash provided by (used for) financing activities     (11,373 )     (34,502 )     26,950       (162,735 )     (887,790 )
Effect of exchange rate changes on cash     371       (152 )     2,136       1,104       4,215  
Net increase (decrease) in cash and cash equivalents     160,376       159,746       143,364       290,204       (402,279 )
Cash and cash equivalents at beginning of period     1,292,301       1,132,555       1,019,109       1,162,473       1,564,752  
Cash and cash equivalents at end of period   $ 1,452,677     $ 1,292,301     $ 1,162,473     $ 1,452,677     $ 1,162,473  
                                         
(1) Derived from audited financial statements  
   
   
Non-GAAP Financial Summary  
(in thousands, except percentages and per share data)  
(unaudited)  
             
    Three Months Ended     Three Months Ended  
    June 29,     March 30,  
    2014     2014  
                 
Revenue   $ 1,248,797     $ 1,227,392  
Gross margin   $ 579,888     $ 558,881  
Gross margin as percentage of revenue     46.4 %     45.5 %
Operating expenses   $ 322,155     $ 311,046  
Operating income   $ 257,733     $ 247,835  
Operating margin as a percentage of revenue     20.6 %     20.2 %
Net income   $ 217,228     $ 216,384  
Net income per diluted share   $ 1.25     $ 1.26  
Shares used in per share calculation - diluted     173,345       171,636  
                 
   
Reconciliation of U.S. GAAP Net Income to Non-GAAP Net Income  
(in thousands, except per share data)  
(unaudited)  
             
    Three Months Ended     Three Months Ended  
    June 29,     March 30,  
    2014     2014  
U.S. GAAP net income   $ 233,395     $ 164,396  
Pre-tax non-GAAP items:                
  Amortization related to intangible assets acquired in Novellus transaction - cost of goods sold     21,685       21,670  
  Costs associated with rationalization of certain product configurations - cost of goods sold     -       4,855  
  Acquisition-related inventory fair value impact - cost of goods sold     1,167       -  
  Synthetic lease impairment - cost of goods sold     -       1,558  
  Amortization related to intangible assets acquired in Novellus transaction - operating expenses     16,547       16,537  
  Restructuring charges - operating expenses     295       -  
  Costs associated with rationalization of certain product configurations - operating expenses     1,086       1,922  
  Cost associated with disposition of business - operating expense     1,103       -  
  Impairment of long lived asset - operating expense     -       4,000  
  Synthetic lease impairment - operating expense     -       5,356  
  Amortization of convertible note discount, Lam notes - other expense, net     7,504       7,416  
  Amortization of convertible note discount, Novellus assumed notes - other expense, net     763       999  
  Gain on sale of real estate     (83,090 )     -  
Net tax expense (benefit) on non-GAAP items     17,075       (12,325 )
Net income tax benefit on sucessful resolution of certain tax matters     (302 )     -  
Non-GAAP net income   $ 217,228     $ 216,384  
Non-GAAP net income per diluted share   $ 1.25     $ 1.26  
Number of shares used for diluted per share calculation     173,345       171,636  
                 

 

             
Reconciliation of U.S. GAAP Gross Margin, Operating Expenses and Operating Income to Non-GAAP Gross Margin, Operating Expenses and Operating Income  
(in thousands, except percentages)  
(unaudited)  
             
    Three Months Ended     Three Months Ended  
    June 29,     March 30,  
    2014     2014  
U.S. GAAP gross margin   $ 557,036     $ 530,798  
Pre-tax non-GAAP items:                
  Amortization related to intangible assets acquired in Novellus transaction - cost of goods sold     21,685       21,670  
  Costs associated with rationalization of certain product configurations - cost of goods sold     -       4,855  
  Acquisition-related inventory fair value impact - cost of goods sold     1,167       -  
  Synthetic lease impairment - cost of goods sold     -       1,558  
Non-GAAP gross margin   $ 579,888     $ 558,881  
U.S. GAAP gross margin as a percentage of revenue     44.6 %     43.2 %
Non-GAAP gross margin as a percentage of revenue     46.4 %     45.5 %
U.S. GAAP operating expenses   $ 341,186     $ 338,861  
Pre-tax non-GAAP items:                
  Amortization related to intangible assets acquired in Novellus transaction - operating expenses     (16,547 )     (16,537 )
  Restructuring charges - operating expenses     (295 )     -  
  Costs associated with rationalization of certain product configurations - operating expenses     (1,086 )     (1,922 )
  Cost associated with disposition of business - operating expense     (1,103 )     -  
  Impairment of long lived asset - operating expense     -       (4,000 )
  Synthetic lease impairment - operating expense     -       (5,356 )
Non-GAAP operating expenses   $ 322,155     $ 311,046  
Non-GAAP operating income   $ 257,733     $ 247,835  
Non-GAAP operating margin as a percent of revenue     20.6 %     20.2 %

Lam Research Corporation Contacts: Carol Raeburn Investor Relations phone: 510-572-4450 e-mail: carol.raeburn@lamresearch.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 352

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 169

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 215

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 221

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 228

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 166

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 284

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 81

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 170

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 176

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading

Top 5 Most Recently Viewed Articles

Citi Confirms Positive Outlook for Nucor with $240 Target

Updated Category News Views 58

Nucor Corporation, a key player in the steel industry, had its Buy rating reaffirmed by Citi, setting a price target of $240. This was no idle gesture; it came hand-in-hand with a revised earnings per share (EPS) estimate dropped to $1.38 from an earlier forecast of $1.76, aligning closely with Nucor’s own guidance that projected an EPS between $1.30 and $1.40 for the...

Continue Reading
Investment Insights: Stanley Druckenmiller's Regional Bank Strategy

Updated Category News Views 288

Understanding Stanley Druckenmiller's Investment Approach Billionaire investor and former hedge fund manager Stanley Druckenmiller is well known for his unique approach to investing. With a knack for macroeconomic analysis, he consistently predicts market movements by taking a top-down view. A Bold Move into Regional Banks Recently, Druckenmiller made headlines with his...

Continue Reading
FFW Corporation Declares Latest Quarterly Dividend Payment

Updated Category News Views 192

FFW Corporation Announces Quarterly Cash Dividend WABASH, Ind. — FFW Corporation (OTC PINK: FFWC), the parent company of Crossroads Bank, has recently announced a quarterly cash dividend of $0.31 per share for its common stock. This dividend will be payable soon, specifically on September 26, and it targets shareholders who are recorded as of September 12. Financial...

Continue Reading
Alaris Equity Partners Secures Final Prospectus for New Offering

Updated Category News Views 101

Alaris Equity Partners Completes Final Prospectus Filing CALGARY, Alberta — Alaris Equity Partners Income Trust, known as Alaris, has made a significant move in its financial strategy by filing a final short form prospectus in various provinces across Canada. This filing aligns with their previously announced offering to secure $100 million in 6.25% convertible...

Continue Reading
Xtreme Fighting Championships Exciting Return to South America

Updated Category News Views 133

Xtreme Fighting Championships Exciting Return to South America Recently, Xtreme Fighting Championships (XFC), backed by Xtreme One Entertainment, Inc. (OTC: XONI), confirmed its much-anticipated return to the vibrant landscape of South America. This marks a significant milestone for the organization, which previously hosted numerous thrilling events in the region....

Continue Reading